Drugs / 26-Valent pneumococcal conjugate vaccine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06970756 | May → Nov 2025 overdue | pneumococcal infection | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06703203 | Jul → Aug 2025 | — | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 26-Valent pneumococcal conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06703203 ↗ |
| Modality | Vaccine | “Biological: 26-Valent pneumococcal conjugate vaccine” NCT06703203 ↗ |
| Route | Intramuscular | “single intramuscular injection” NCT06970756 ↗ |